Experienced in Leukemia
Experienced in Leukemia
Rutgers Health-Rwj Scleroderma Program
195 Little Albany St, 
New Brunswick, NJ 

Overview

Richard Drachtman is a Hematologist in New Brunswick, New Jersey. Dr. Drachtman is rated as an Experienced provider by MediFind in the treatment of Leukemia. His top areas of expertise are Hodgkin Lymphoma, Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 36 peer reviewed articles and participating in 46 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles and participated in 16 clinical trials in the study of Leukemia.

Specialties
Hematology
Licenses
Pediatrics in NJ
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 2 Less Insurance Carriers -

Locations

RUTGERS HEALTH-RWJ SCLERODERMA PROGRAM
195 Little Albany St, New Brunswick, NJ 08901

Additional Areas of Focus

Dr. Drachtman has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


46 Clinical Trials

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Renal Tumors Classification, Biology, and Banking Study
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
A Phase II Study for the Treatment of Non-metastatic Nodular Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age
View 42 Less Clinical Trials
Similar Doctors
Elite in Leukemia
Hematology | Oncology
Elite in Leukemia
Hematology | Oncology

Memorial Hematology Lymphoma Group

530 E 74th St, 
New York, NY 
 (32.1 miles away)
Languages Spoken:
English
Offers Telehealth

Eytan Stein is a Hematologist and an Oncologist in New York, New York. Dr. Stein is rated as an Elite provider by MediFind in the treatment of Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

Elite in Leukemia
Elite in Leukemia

Memorial Hematology Lymphoma Group

1275 York Ave, 
New York, NY 
 (31.8 miles away)
Languages Spoken:
English
Offers Telehealth

Michael Mauro is a Hematologist in New York, New York. Dr. Mauro is rated as an Elite provider by MediFind in the treatment of Leukemia. His top areas of expertise are Chronic Myelogenous Leukemia (CML), Leukemia, Myeloproliferative Neoplasms (MPN), Bone Marrow Aspiration, and Bone Marrow Transplant.

Jonathan E. Kolitz
Elite in Leukemia
Elite in Leukemia

Northwell Health Center For Advanced Medicine, RJ Zuckerberg Cancer Center

450 Lakeville Road, Entrance B, 
Lake Success, NY 
 (43.1 miles away)
Languages Spoken:
English, Spanish
Offers Telehealth

Jonathan Kolitz, MD, FACP, is Professor of Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. An expert in malignant hematology, he is the System Head for Malignant Hematology for the Northwell Health Cancer Institute where he guides the clinical care and research activities of faculty and fellows. Board certified in Internal Medicine, Hematology and Medical Oncology, Dr. Kolitz has been a member of the Leukemia Core Committee of the CALGB/Alliance since 1993. He has focused on the development, conduct and publication of innovative clinical trials for the treatment of hematologic malignancies, especially acute leukemia. He has been principal investigator for numerous novel drug trials and has been involved in multiple national and international collaborations, leading to over 200 publications. As an attending physician at the Monter Cancer Center, Dr. Kolitz focuses on providing compassionate, personalized, evidence-based care. Dr. Kolitz earned his medical degree from the Yale University School of Medicine. He trained in Internal Medicine at North Shore University Hospital and Hematology and Medical Oncology at Memorial Sloan-Kettering Cancer Center. Dr. Kolitz is an active member of the American Society of Hematology, American Society of Clinical Oncology and the American College of Physicians. Dr. Kolitz is rated as an Elite provider by MediFind in the treatment of Leukemia. His top areas of expertise are Leukemia, Chronic B-Cell Leukemia (CBCL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Drachtman's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 22 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile